From: COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
COVID-19 patients, N pts/N evaluable (%) | RNA-positive subgroup, N pts/N evaluable (%) | |
---|---|---|
Early breast cancer patients | N = 22 | N = 22 |
Surgery* | 3/22 (14%) | 3/22 (14%) |
Chemotherapy | 8/22 (36%) | 8/22 (36%) |
Epirubicin and cyclophosphamide | 5/22 (23%) | 5/22 (23%) |
Paclitaxel/docetaxel | 2/22 (9%) | 2/22 (9%) |
Radiation therapy | 2/22 (9%) | 2/22 (9%) |
Endocrine therapy | 4/22 (18%) | 4/22 (18%) |
Anti-estrogens | 3/22 (14%) | 3/22 (14%) |
Aromatase inhibitors | 1/22 (4%) | 1/22 (4%) |
Targeted therapy | 3/22 (14%) | 3/22 (14%) |
Trastuzumab | 2/22 (9%) | 2/22 (9%) |
Pertuzumab | 1/22 (4%) | 1/22 (4%) |
Trastuzumab emtansine | 1/22 (4%) | 1/22 (4%) |
None | 6/22 (27%) | 6/22 (27%) |
Pending surgery | 5/22 (23%) | 5/22 (23%) |
Pending radiation therapy | 1/22 (4%) | 1/22 (4%) |
Combination of any treatment | 3/22 (14%) | 3/22 (14%) |
Metastastic breast cancer patients | N = 37 | N = 19 |
Surgery* | 0 (0%) | 0 (0%) |
Chemotherapy | 21/37 (57%) | 10/19 (53%) |
Capecitabine | 7/37 (19%) | 4/19 (21%) |
Paclitaxel/docetaxel | 6/37 (16%) | 3/19 (16%) |
Epirubicin and cyclophosphamide | 1/37 (3%) | 0 (0%) |
Vinorelbine | 2/37 (5%) | 0 (0%) |
Eribulin | 1/37 (3%) | 1/19 (5%) |
Gemcitabine | 2/37 (5%) | 1/19 (5%) |
Carboplatin | 3/37 (8%) | 1/19 (5%) |
Intrathecal chemotherapy | 2/37 (5%) | 2/19 (10%) |
Radiation therapy | 2/37 (5%) | 2/19 (10%) |
Endocrine therapy | 15/37 (40%) | 7/19 (37%) |
Anti-estrogens | 3/37 (8%) | 1/19 (5%) |
Aromatase inhibitors | 11/37 (30%) | 6/19 (32%) |
Selective estrogen receptor degrader | 1/37 (3%) | 0 (0%) |
Targeted therapy | 16/37 (43%) | 7/19 (37%) |
CDK4/6 inhibitor | 9/37 (24%) | 5/19 (26%) |
Trastuzumab | 5/37 (13%) | 2/19 (10%) |
Pertuzumab | 4/37 (11%) | 2/19 (10%) |
Everolimus** | 2/37 (5%) | 0 (0%) |
Immunotherapy | 0 (0%) | 0 (0%) |
Combination of any treatment | 21/37 (57%) | 8/19 (42%) |
None | 1/37 (3%) | 1/19 (5%) |
Total | N = 59 | N = 41 |